These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12477312)

  • 1. Development of vaccines for bio-warfare agents.
    Rosenthal SR; Clifford JC
    Dev Biol (Basel); 2002; 110():99-105. PubMed ID: 12477312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difficulties associated with the development and licensing of vaccines for protection against bio-warfare and bio-terrorism.
    Langford MJ; Myers RC
    Dev Biol (Basel); 2002; 110():107-12. PubMed ID: 12477313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines against biologic agents: uses and developments.
    Ales NC; Katial RK
    Respir Care Clin N Am; 2004 Mar; 10(1):123-46. PubMed ID: 15062232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plants as biofactories for the production of subunit vaccines against bio-security-related bacteria and viruses.
    Rigano MM; Manna C; Giulini A; Vitale A; Cardi T
    Vaccine; 2009 May; 27(25-26):3463-6. PubMed ID: 19460602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines, pharmaceutical products, and bioterrorism: challenges for the U.S. Food and Drug Administration.
    Zoon KC
    Emerg Infect Dis; 1999; 5(4):534-6. PubMed ID: 10458960
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjusting FDA policies to address bioterrorist threat.
    Fox JL
    Nat Biotechnol; 1999 Apr; 17(4):323-4. PubMed ID: 10207870
    [No Abstract]   [Full Text] [Related]  

  • 8. Vaccine development: the biological weapon imperative.
    Robertson AG
    Dev Biol (Basel); 2002; 110():91-7. PubMed ID: 12477311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part II.
    Giacoia GP; Mattison DR
    Clin Ther; 2006 Sep; 28(9):1337-41. PubMed ID: 17062307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Project BioShield: what it is, why it is needed, and its accomplishments so far.
    Russell PK
    Clin Infect Dis; 2007 Jul; 45 Suppl 1():S68-72. PubMed ID: 17582574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Particulate delivery systems for biodefense subunit vaccines.
    Bramwell VW; Eyles JE; Oya Alpar H
    Adv Drug Deliv Rev; 2005 Jun; 57(9):1247-65. PubMed ID: 15935873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technological advancements for the detection of and protection against biological and chemical warfare agents.
    Eubanks LM; Dickerson TJ; Janda KD
    Chem Soc Rev; 2007 Mar; 36(3):458-70. PubMed ID: 17325785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax.
    Meyerhoff A; Albrecht R; Meyer JM; Dionne P; Higgins K; Murphy D
    Clin Infect Dis; 2004 Aug; 39(3):303-8. PubMed ID: 15306995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States.
    Lee MH; Arcidiacono JA; Bilek AM; Wille JJ; Hamill CA; Wonnacott KM; Wells MA; Oh SS
    Tissue Eng Part B Rev; 2010 Feb; 16(1):41-54. PubMed ID: 19728784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines and bioterrorism: smallpox and anthrax.
    Kimmel SR; Mahoney MC; Zimmerman RK
    J Fam Pract; 2003 Jan; 52(1 Suppl):S56-61. PubMed ID: 12556279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Criteria supporting the study of drugs in the newborn.
    Ward RM; Benitz WE; Benjamin DK; Blackmon L; Giacoia GP; Hudak M; Lasky T; Rodriguez W; Selen A
    Clin Ther; 2006 Sep; 28(9):1385-98. PubMed ID: 17062311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization against potential biological warfare agents.
    Cieslak TJ; Christopher GW; Kortepeter MG; Rowe JR; Pavlin JA; Culpepper RC; Eitzen EM
    Clin Infect Dis; 2000 Jun; 30(6):843-50. PubMed ID: 10880299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.